OBJECTIVES: The herpesviridae family includes, among others, herpes simplex virus, varicella zoster virus, Epstein-Barr virus, and cytomegalovirus. Herpesviridae viral infections (HVIs) can lead to serious complications in lymphoma patients undergoing chemotherapy. There is no consensus on the dose and duration of antiviral prophylaxis in these patients. We retrospectively analyzed the incidence and risk factors for HVI in lymphoma patients undergoing chemotherapy. METHODS: We reviewed the records of 266 patients who were newly diagnosed with lymphoma and received chemotherapy without acyclovir prophylaxis between June 1996 and August 2009. RESULTS: The cumulative incidence rate of HVI was 20.16% for 5 years from the start of chemotherapy. Independent predictive factors for HVI in lymphoma patients were: female sex [hazard ratio (HR) 2.394; 95% confidence interval (CI): 1.245-4.607; P=0.009], cumulative dose of steroids per body surface area of at least 2500 mg/m(2) (HR 7.717; 95% CI: 3.814-18.703; P<0.001), and history of neutropenic fever (HR 0.297; 95% CI: 0.150-0.588; P<0.001). CONCLUSIONS: Female sex, high dose of steroids per body surface area, and neutropenic fever were risk factors for HVI in patients with lymphoma undergoing chemotherapy without acyclovir prophylaxis.
OBJECTIVES: The herpesviridae family includes, among others, herpes simplex virus, varicella zoster virus, Epstein-Barr virus, and cytomegalovirus. Herpesviridae viral infections (HVIs) can lead to serious complications in lymphomapatients undergoing chemotherapy. There is no consensus on the dose and duration of antiviral prophylaxis in these patients. We retrospectively analyzed the incidence and risk factors for HVI in lymphomapatients undergoing chemotherapy. METHODS: We reviewed the records of 266 patients who were newly diagnosed with lymphoma and received chemotherapy without acyclovir prophylaxis between June 1996 and August 2009. RESULTS: The cumulative incidence rate of HVI was 20.16% for 5 years from the start of chemotherapy. Independent predictive factors for HVI in lymphomapatients were: female sex [hazard ratio (HR) 2.394; 95% confidence interval (CI): 1.245-4.607; P=0.009], cumulative dose of steroids per body surface area of at least 2500 mg/m(2) (HR 7.717; 95% CI: 3.814-18.703; P<0.001), and history of neutropenic fever (HR 0.297; 95% CI: 0.150-0.588; P<0.001). CONCLUSIONS: Female sex, high dose of steroids per body surface area, and neutropenic fever were risk factors for HVI in patients with lymphoma undergoing chemotherapy without acyclovir prophylaxis.
Authors: J-H Ko; K R Peck; W J Lee; K Huh; J R Yoo; K Kim; S Y Cho; Y E Ha; C-I Kang; D R Chung; C W Jung; Y-H Kim; N Y Lee; K-M Kim; J-H Song Journal: Eur J Clin Microbiol Infect Dis Date: 2014-05-23 Impact factor: 3.267
Authors: Elie Azoulay; Lene Russell; Andry Van de Louw; Victoria Metaxa; Philippe Bauer; Pedro Povoa; José Garnacho Montero; Ignacio Martin Loeches; Sangeeta Mehta; Kathryn Puxty; Peter Schellongowski; Jordi Rello; Djamel Mokart; Virginie Lemiale; Adrien Mirouse Journal: Intensive Care Med Date: 2020-02-07 Impact factor: 17.440
Authors: Larissa Henze; Christoph Buhl; Michael Sandherr; Oliver A Cornely; Werner J Heinz; Yascha Khodamoradi; Til Ramon Kiderlen; Philipp Koehler; Alrun Seidler; Rosanne Sprute; Martin Schmidt-Hieber; Marie von Lilienfeld-Toal Journal: Ann Hematol Date: 2022-01-07 Impact factor: 3.673
Authors: Maria A Stacey; Morgan Marsden; Tu Anh Pham N; Simon Clare; Garry Dolton; Gabrielle Stack; Emma Jones; Paul Klenerman; Awen M Gallimore; Philip R Taylor; Robert J Snelgrove; Trevor D Lawley; Gordon Dougan; Chris A Benedict; Simon A Jones; Gavin W G Wilkinson; Ian R Humphreys Journal: Cell Host Microbe Date: 2014-04-09 Impact factor: 21.023